Sanford Burnham Prebys’ Post

Unimolecular Self-Assembled Hemicyanine–Oleic Acid Conjugate Acts as a Novel Succinate Dehydrogenase Inhibitor to Amplify Photodynamic Therapy and Eliminate Cancer Stem Cells AAAS https://lnkd.in/gMZRxD7X

Discover more about #Medexus’ exciting opportunity with their treosulfan pipeline. Treosulfan, part of a conditioning treatment for allogeneic hematopoietic stem cell transplantation (allo-HSCT), gained approval from Health Canada in June 2021, launching commercially as Trecondyv®. What’s new here is that Medexus just announced the FDA’s acceptance for review of the treosulfan NDA, expecting a decision by October 30th, 2024. If approved, Medexus stands to launch treosulfan in the US market, where they estimate the current leading product generated ~US$126 million in peak annual revenue before genericization in 2018. Learn more about treosulfan, a pipeline opportunity for Medexus, during our Adelaide Capital Investor Update. RSVP for the June 14 webinar: https://lnkd.in/efSSB2kK #MedexusPharmaceuticals #TSX #MDP #OTCQX #MEDXF

[Ensuring the successful growth of your organoids with ATCC® Organoid Growth Kits] Organoids are valuable tools to study cancer, identify and target novel therapies, and facilitate translational cancer research. In efforts to simplify Organoid culture, ATCC® has developed Organoid Growth Kits which are comprised of single-use supplements created to streamline media preparation. These kits contain the most costly and cumbersome supplements and reagents, reducing the time and effort required to prepare media and ensuring the successful growth of your organoids. Welcome to contact ours specialists, or explore the ATCC® Organoid Growth Kits at WWW.ATCC.ORG/ORGANOIDKITS #tinhang #atcc #organoids #organoidgrowthkit #cellline #cellculture #cancer #therapies #lifescience #research #clinical #laboratory

Hello Folks! My first post is out! Exciting advancements in CAR T cell therapy, particularly allogeneic approaches, hold promise for revolutionizing cancer treatment. Allogeneic therapies, such as those developed by Allogene Therapeutics, utilize T cells from healthy donors, offering a scalable and accessible alternative to traditional autologous therapies. Innovations in suicide gene systems and gene editing technologies enhance safety and efficacy. Regulatory considerations, including patient enrollment challenges, risk-benefit assessments, and manufacturing requirements, are crucial for ensuring patient safety and treatment efficacy. By addressing these considerations and advancing innovative products, allogeneic CAR T cell therapies have the potential to transform the landscape of cancer treatment. #CARTtherapy #Oncology #RegulatoryConsiderations #Healthcare #Innovation Please do give this a read!

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/dR-ntd3m

New study identifies 2 key factors that impact the outcomes of #allogenic CD19 directed CAR NK cells. Cord blood units that were cryopreserved within 24 hours of collection and those with a low nucleated red blood cell content were associated with markedly better outcomes. #celltherapy #CARNKcells #CD19 #allogenic #Bcell #lymphoma #mdanderson

We’ve already seen approvals for CAR-T cell therapies, but what’s next? In this article, we outline the current cell therapy environment, examine key strategies for execution, and identify ways to add efficiency throughout development. https://hubs.ly/Q01Yg90Y0 #oncology #clinicaltrials #celltherapy

This November, capivasertib (TRUQAP®) received approval by the FDA as a medicine for treating estrogen receptor (ER)-positive metastatic breast cancer (MBC) in adults. It acts as an inhibitor of AKT1, AKT2, and AKT3 isoforms of serine/threonine kinase AKT (protein kinase B) that results in inhibiting the phosphorylation of substrates in the AKT signaling pathway. The AKT kinase plays a crucial role in regulating many processes including metabolism, cell survival, growth, and proliferation. Mutations and loss of functions in the AKT pathway are among the most common reasons for breast cancer. Capivasertib contains piperidine-4-amine moiety in its backbone. To support your further research, we have made a set of Building Blocks that contain such cores, which could be a promising starting point in your research projects! https://buff.ly/47UC6wI #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures

Labcorp’s disseminated NALM6-Luc-mCh-Puro ALL model in NSG mice, established by our teams in house, provides yet another tool for the preclinical development of therapies directed against B-cell malignancies. We have characterized the response to CD19-targeted CAR T cell treatment and evaluated the activity and persistence using flow cytometry with expanded Persistence T panels. Find out more: https://lnkd.in/ghwwRsPf #AcuteLymphoblasticLeukemia #TumorModel #FlowCytometry